The FDA on March 4, 2022 approved OPDIVO® with platinum-doublet chemotherapy for adult patients with resectable Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant setting. OPDIVO® is a product of Bristol-Myers Squibb Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
